SK Phamateco to set up a new peptide plant

SK Pharmteco, a contract development and manufacturing organization, plans to invest $260 million in a peptide and small-molecule drug production plant in Sejong, South Korea. The 12,600 m 2 facility will be the company’s fifth plant in that country. SK Pharmteco says the plant will be operational in late 2026 and add 300 employees to its workforce. The high global demand for peptides is fueled in part by the popularity of glucagon-like peptide-1 drugs, such as those developed by Novo Nordisk and Eli Lilly and Company.